NAUTA PHARMACOCHEMISTRY AWARD FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY
Prof. Herbert Waldmann
Max Planck Institute of Molecular Physiology, Germany
For his pioneering contribution to medicinal chemistry and chemical biology, and for the broad range of breakthrough concepts that laid the foundation of chemical biology as a discipline. Herbert Waldmann’s research is deeply interdisciplinary and further includes influential articles covering cell-based screening, activity-based protein profiling and chemical proteomics, genetics, and biophysics methodologies. Noteworthy, he fostered Europe’s scientific community through many partnerships across academia and industry and through his numerous scientific offspring.
The EFMC is pleased to announce that the recipient of the 2022 Nauta Award for outstanding achievements in the field of Medicinal Chemistry and Chemical Biology is Professor Herbert Waldmann.
THE UCB-EHRLICH AWARD for EXCELLENCE IN MEDICINAL CHEMISTRY
Prof. Mike Waring
University of Newcastle, United Kingdom
For his conceptual work on the role of lipophilicity and for the contribution to advance the field of covalent inhibitors in medicinal chemistry. Mike Waring has been involved in drug discovery and development projects that resulted in several drug candidates reaching clinical trials, including the EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer. Overall, he has made impactful contributions to small molecule drug discovery using novel hit generation approaches such as DNA encoded libraries and fragment-based lead generation
The EFMC is pleased to announce that the recipient of the 2022 UCB – Ehrlich Award for outstanding research into natural products and chemical biology is Professor Mike Waring.
THE PROUS INSTITUTE - OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Prof. Alessio Ciulli
University of Dundee, United Kingdom
For his pioneering work in the field of proteolysis-targeting chimera (PROTAC) technology for drug-induced targeted protein degradation. He has made substantial contributions to the development of new ligands of von Hippel-Lindau (VHL) E3 ligase, specifically bivalent small-molecule dimerisers of the VHL E3 ubiquitin ligase (VHL-based PROTACs) and elucidated their mechanism of action. Notably, Alessio Ciulli’s research provided a rational basis for the design and optimisation of the next generation of targeted protein degradation systems.
The EFMC is pleased to announce that the recipient of the 2022 Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery is Professor Alessio Ciulli.
The Selection Committees are proud to announce the names of the winner and the most meritorious runners-up of the EFMC Prize for a Young Medicinal Chemist in Industry and the EFMC Prize for a Young Medicinal Chemist in Academia.
EFMC PRIZE FOR YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN ACADEMIA
The selection committee designated Prof. Olalla Vazquez, Philipps-Universität Marburg, Germany, as the winner of the 2022 EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia.
Prof. Tiago Rodrigues, University of Lisbon, Portugal, and Dr Cristina Mayor Ruiz, IRB Barcelona, Spain, have been recognised as the most meritorious runners-up.
EFMC PRIZE FOR YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN INDUSTRY
The selection committee designated Dr Marie-Hélène Larraufie , Almirall, Spain, as the winner of the 2022 EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry.
Dr Nadine Schneider, Novartis, Switzerland, has been recognised as the most meritorious runner-up
Michael E. Jung, Head of the Department of Chemistry and Biochemistry at UCLA, has been awarded the 2022 IUPAC-Richter Prize in recognition of his research, which has afforded new drugs for the treatment of advanced prostate cancer.